openPR Logo
Press release

US Biosimilars Market Opportunity & Clinical Pipeline Analysis Report

05-07-2018 09:04 AM CET | Health & Medicine

Press release from: Kuick Resarch

US Biosimilars Market Opportunity & Clinical Pipeline Analysis

“US Biosimilars Market Opportunity & Clinical Pipeline Analysis” Report Highlight:

* US Biosimilars Market Introduction
* US Biosimilars Regulatory Scenario
* Unique Features of US Biosimilars Market
* Impact of Biosimilars in US Market
* Impact of Reimbursement Policies on US Biosimilars Market
* Zarxio: First Approved Biosimilar in US
* US Biosimilar Clinical Pipeline By Company, Indication & Phase
* US Biosimilar Clinical Pipeline: 104 Biosimilars
* Marketed Biosimilars: 1 Biosimilar

Download Report Sample Weblink:

https://www.kuickresearch.com/report-US-Biosimilars-Market-Opportunity-&-Clinical-Pipeline-Analysis.php

For Report Sample Contact: neeraj@kuickresearch.com

Table of Contents

1. US Biosimilars Market Introduction



2. US Biosimilars Regulatory Scenario



3. Unique Features of US Biosimilars Market



4. Impact of Biosimilars in US Market



5. New Biosimilar Categories with High Commercialization Potential

5.1 High Cost-Effectiveness

5.2 Competition

5.3 Nature of Indication

5.4 Nature of Biosimilars

5.5 Cost-Effective Production

5.6 Readily Availability of Biosimilars



6. Impact of Reimbursement Policies on US Biosimilars Market



7. Biobetters: Middle Ground between Biosimilars & Biologics



8. US Biosimilars Market Overview

8.1 Current Market Scenario

8.2 US Biosimilar Clincal Pipeline Overview



9. Zarxio: First Approved Biosimilar in US



10. US Biosimilars Market Dynamics

10.1 Research & Development

10.2 Increasing Demand for Biosimilars

10.3 Increasing Numbers Off-Patent Biologics

10.4 Lesser Competition

10.5 Strong Clinical Pipeline

10.6 Large Number of Indications to be Introduced



11. US Biosimilars Commercialization Challenges



12. US Biosimilars Future Prospects



13. US Biosimilars Market Guidelines

13.1 Scientific Considerations in Demonstration Biosimilarity to a Reference Product

13.2 Quality Considerations in Demonstrating Biosimilarity of a Therapeutic Protein

Product to a Reference Product

13.3 Nonproprietary Naming of Biological Products

13.4 Clinical Pharmacology Data to Support a Demonstration of Biosimilarity to a

Reference Product



14. US Biosimilar Clinical Pipeline By Company, Indication & Phase

14.1 Research

14.2 Preclinical

14.3 Phase-I

14.4 Phase-I/II

14.5 Phase-II

14.6 Phase-III

14.7 Preregistration

14.8 Registered



15. Suspended & Discontued Biosimialrs in Clinical Pipeline

15.1 No Development Reported

15.2 Discountinued

15.3 Preregistration Submission Withdrawal



16. Competitive Landscape

16.1 Amgen

16.2 Apotex

16.3 Boehringer Ingelheim

16.4 Celltrion

16.5 Coherus BioSciences

16.6 Eli Lilly

16.7 EPIRUS Biopharmaceuticals

16.8 Finox Biotech

16.9 Harvest Moon Pharmaceuticals

16.10 Hospira

16.11 Intas Biopharmaceuticals

16.12 Juno Therepeutics (Opus Bio)

16.13 Merck

16.14 Momenta Pharmaceuticals

16.15 Mylan

16.16 Nora Therapeutics

16.17 Novartis

16.18 Oncobiologics

16.19 Pfenex

16.20 Pfizer

16.21 Sandoz

16.22 Wockhardt

Figure 1-1: Benefits of Biosimilar Introduction in US

Figure 1-2: Present Limitations of Biosimilars in US

Figure 1-3: FDA’s Requirements for Biosimilar Products

Figure 2-1: Criterias for Similarity Formulated by Food and Drug Administration (FDA)

Figure 4-1: Global Sales of Neupogen/Neulasta (USD Million), 2012-2014

Figure 4-2: Global Sales of Epogen (USD Million), 2012-2014

Figure 4-3: Global Sales of Neulasta (USD Million), 2012-2014

Figure 4-4: Shares of Amgen Products Exposed to Biosimilars Competition (USD Million), 2014

Figure 5-1: Factors Responsible for Significant Revenue Generation

Figure 7-1: Properties of Biobetters

Figure 7-2: Few Advantages of Biobetters

Figure 7-3: Disadvantages of Biobetters

Figure 8-1: US- Estimated Humira Sales (USD Million), 2012-2014

Figure 8-2: Global Remicade Sales (USD Million), 2012-2014

Figure 8-3: US- MabThera/Rituxan Quarterly Constant Exchange Rate Sales Growth (USD Million), Q3 2014-Q3 2015

Figure 8-4: US-Herceptin Quarterly Constant Exchange Rate Sales Growth (USD Million), Q3 2014- Q3 2015

Figure 8-5: Global Herceptin Quarterly Constant Exchange Rate Sales Growth (USD Million), Q3 2014-Q3 2015

Figure 8-6: Estimated Global Aranesp Sales (USD Million), 2012-2014

Figure 8-7: US- Estimated Aranesp Sales (USD Million), 2012-2017

Figure 8-8: Estimated Sales of Selected Biologics Exposed to Biosimilars Competition, 2014 (USD Million)

Figure 8-9: Estimated Shares of Selected Biologics Exposed to Biosimilars Competition (USD Million), 2014

Figure 8-10: Rank of US among Different Diabetes Prone Countries

Figure 8-11: US Biosimilar Pipeline by Phase (%),2016

Figure 8-12: US Biosimilar Pipeline by Phase (Number),2016

Figure 8-13: No Development Reported US Biosimilar All Pipeline by Phase (%),2016

Figure 8-14: No Development Reported US Biosimilar All Pipeline by Phase (Number),2016

Figure 8-15: Discontinued US Biosimilar All Pipeline by Phase (%),2016

Figure 8-16: Discontinued US Biosimilar All Pipeline by Phase (Numbers),2016

Figure 16-1: Amgen Clinical Pipeline

Figure 16-2: Coherus Bioscience Clinical Pipeline

Figure 16-3: EPIRUS Biopharmaceuticals- Clinical Pipeline

Figure 16-4: Merck Clinical Pipeline

Figure 16-5: Novartis Clinical Pipeline

Figure 16-6: Oncobiologics-Clinical Pipeline

Figure 16-7: Pfenex Clinical Piepline

Figure 16-8: Sandoz Clinical Pipeline



List of Tables



Table 2-1: Major Regulatory Differences Related to Biosimilars in US & EU

Table 2-2: Differences between Biosimilars Applications & Biologics License Applications

Table 4-1: Comparison of Neupogen vs. Zarxio Cost

Table 4-2: Competition to Neupogen

Table 4-3: Amgen’s Biosimilar Competitors in US

Table 4-4: Categories with Potential to Generate Significant Revenues in US Market

Table 5-1: Biosimilars under Food and Drug Administration (FDA) Review

Table 6-1: Categories of Medicare Plan

Table 6-2: Estimated Reimbursement of Zarxio according to Medicare B

Table 7-1: Few Examples of Biologics, Biosimilars and Biobetters

Table 8-1: Biosimilars with High Commercialization Potential in US, 2013-2024

Table 8-2: Companies Involved in Marketing of Rituximab

Table 8-3: Categories with High Potential for Biosimilar Revenue Generation

Table 16-1: Celltrion Clinical Pipeline

Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas. By translating research answers into strategic insight and direction, we not only rate the success potential of your products and/or services, but also help you identify the opportunities for growth in new demographies and find ways to beat competition.

Neeraj Chawla
neeraj@kuickresearch.com
KuicK Research
L29 - L34, First Floor
Block L,Connaught Place
New Delhi-110001
+91-11-47067990

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release US Biosimilars Market Opportunity & Clinical Pipeline Analysis Report here

News-ID: 1040986 • Views: 617

More Releases from Kuick Resarch

Global Cell Therapy Market To Surpass US$ 35 Billion By 2026
Global cell therapy market is expected to surpass US$ 35 Billion by 2026 as per recent report “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” published by Kuick Research. Increasing investment, gaining research and development activities along with new technological advancement will drive the global cell therapy market. Download Report: https://www.kuickresearch.com/report-global-cell-therapy-market,-clinical-trials,-therapy-price-and-opportunity-insight-2026.php “Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026” Report Highlights: • Global Cell Therapy
Cell Therapy Market Size Growth Cell Therapy Clinical Trials Market Forecast 202 …
Cell therapies are still in the infancy stages of the clinical development and are expected to evolve in the market with a vast number of opportunities in the healthcare industry. In order to form a stable base for process evaluation and development it will be essential to understand the quality of cell based products. With an increasing number of cell therapies and clinical indications being assessed, it is clear that
Global Cell Therapy Market Size Analysis Clinical Trials Growth Forecast 2026
"Global Cell Therapy Market, Clinical Trials, Therapy Price & Opportunity Insight 2026" Report Highlights: • Global Cell Therapy Market Opportunity: More Than US$ 35 Billion by 2026 • Cell Therapy Clinical Trial Insight by Indication, Company & Country • Global Cell Therapy Clinical Pipeline: 767 Cell Therapies • Globally Marketed Cell Therapies: 25 Cell Therapies • Maximum Number of Marketed Cell Therapies In USA: 15 Therapies • Price & Product Insight By Region/Country • Regional Analysis of the Cell Therapy Market Download
CAR T Cell Therapy Changing The Cancer Oncology Drug Market Landscape
" Global CAR T Cell Therapy Market & Clinical Trials Insight 2024" Report Highlights: • CAR T-Cell Therapies Delivery Pipeline & Mechanism of Action • Sales Analysis of CAR - T Cell Therapy • CAR - T Cell Therapy Market Opportunity: US$ 700 Million • CAR-T Cell Therapies Clinical Pipeline by Company, Indication & Phase: 236 Therapies • CAR-T Cell Therapies in Highest Phase: Preclinical • Marketed CAR-T Cell Therapies: 2 ( Yescarta & Kymriah) • Global Market Scenario of

All 5 Releases


More Releases for Bio

Global Bio Polyurethane (Bio-based Polyurethane) Market 2018 - BASF, Lubrizol
Apex Market Reports, recently published a detailed market research study focused on the “Bio Polyurethane (Bio-based Polyurethane) Market” across the global, regional and country level. The report provides 360° analysis of “Bio Polyurethane (Bio-based Polyurethane) Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend
Global Bioplastics (Bio-plastics,Bio plastics) Market 2018 - Braskem, BASF
Apex Market Reports, recently published a detailed market research study focused on the “Bioplastics (Bio-plastics,Bio plastics) Market” across the global, regional and country level. The report provides 360° analysis of “Bioplastics (Bio-plastics,Bio plastics) Market” from view of manufacturers, regions, product types and end industries. The research report analyses and provides the historical data along with current performance of the global PP Pipe industry, and estimates the future trend of Bioplastics
Bio Electronics and Bio Sensors Market Forecasts, 2017-2025
Description: The global bio electronic market is valued USD $15 billion in 2016 and is expected to grow at a CAGR of 11.6% during the forecast period 2017-2025. The market is driven by various factors such as rapid advancement in semiconductor technology, high demand in implantable medical devices, increasing prevalence of neural and cardiac diseases among others. The emerging healthcare technologies such as lab on chip, ambulatory surgical centres, and personalized devices are
Bio Simulation Technology Market
Global Bio Simulation Technology Industry Bio Simulation Technology Market is estimated at $1.01 billion in 2015 and is projected to reach $2.99 billion by 2022 growing at a CAGR of 16.6% from 2015 to 2022. Reduction in the cost of drug discovery and development and risk of failure of drug molecule are some of the factors driving the market growth. Furthermore, R&D investments in biotechnology and pharmaceutical industries, growth in the
Global Bio-Polyethylene Terephthalate (Bio-PET) Market Research Report 2021
Qyresearchreports include new market research report “Global Bio-Polyethylene Terephthalate (Bio-PET) Market Research Report 2021″ to its huge collection of research reports. This market intelligence report serves its readers with an executive-level blueprint of the global Bio-Polyethylene Terephthalate (Bio-PET) market. Data from a number of paid and unpaid sources including press releases, journals, presentations, and white papers has been taken into account for collating this report. The various factors influencing the growth of
SHANE RADBONE CORPORATE BIO
Young, dynamic and highly successful Shane founded his own business, Executive Fitness Management at age 20 in 1991. After a successful career in football that took him as high as playing for Essendon, Shane appreciated the need to have more than just sport in his portfolio. However taking his on field attitude to the corporate arena, Executive Fitness Management (EFM) grew into Australia’s largest Corporate Fitness Company. It started with